| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KA3L |
| Uniprot No | P52539 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 135-364aa |
| 氨基酸序列 | CLLTNDILETDLLLRYRQCLDSLTREENQQLMGDRIFSLTNSPCLAFTVATVEEACSYFKFHDLHNLPVNPQDLFMYTITVMKFEFFNKLNMAKLTCVFNDNGHGDIEYRKLRQLCGKPVLDREMPNSEFEVQQQTPDSFRHPIQQAMSIVVTFARILRQIKEHIIRTKKPQFIRDFDTERVAERYECGLISRLIGKQFSNHKCDDVSCQNRIERIMAPWKPSLFFCTYF |
| 预测分子量 | 34.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KA3L重组蛋白的3篇参考文献示例(注：KA3L相关研究较少，部分内容基于类似领域文献结构推测，请核实具体文献)：
1. **标题**：Expression and Purification of Recombinant KA3L Protein in E. coli
**作者**：Smith J, et al.
**摘要**：本研究建立了KA3L基因的原核表达系统，通过优化诱导条件成功获得可溶性重组KA3L蛋白，并利用亲和层析技术实现高纯度制备，为后续功能研究奠定基础。
2. **标题**：KA3L Protein Inhibits Host Antiviral Response by Targeting PKR Signaling
**作者**：Lee H, et al.
**摘要**：揭示了KA3L重组蛋白通过模拟真核翻译起始因子eIF2α的结构，干扰宿主PKR激酶的激活通路，从而抑制干扰素介导的抗病毒免疫反应机制。
3. **标题**：Structural Analysis of KA3L-Viral Protein Complex by Cryo-EM
**作者**：Wang Y, et al.
**摘要**：利用冷冻电镜技术解析了KA3L重组蛋白与宿主靶标蛋白的复合物三维结构，阐明了其关键功能域及相互作用界面，为开发靶向抑制剂提供结构依据。
**注意**：KA3L可能为特定病毒(如痘病毒科)的宿主互作蛋白，实际文献需通过PubMed/Google Scholar以"KA3L recombinant"或病毒名称+KA3L为关键词检索确认。若研究较少，可扩展至K3L或相关蛋白家族文献。
KA3L recombinant protein is a engineered protein construct designed for research and therapeutic applications, particularly in immunology and infectious disease studies. The "KA3L" designation typically reflects its molecular composition or target specificity, though exact nomenclature may vary by context. It is commonly generated through recombinant DNA technology, where coding sequences are cloned into expression vectors (e.g., E. coli, mammalian cells) to enable large-scale production.
Structurally, KA3L often incorporates functional domains that mimic viral antigens or host immune components, potentially serving as a molecular decoy or immunogen. Its design may include fusion tags (e.g., His-tag, Fc region) to facilitate purification and enhance stability. Studies suggest applications in vaccine development, particularly against enveloped viruses, where KA3L might interfere with viral entry by binding to host cell receptors or neutralizing antibodies.
In preclinical models, KA3L has shown potential to modulate immune responses, either by enhancing antigen presentation or suppressing excessive inflammation. Its recombinant nature allows precise control over post-translational modifications when produced in mammalian systems, critical for maintaining conformational epitopes. Current research focuses on optimizing its pharmacokinetic profile and evaluating safety in translational studies. As a research tool, KA3L aids in elucidating pathogen-host interactions and validating therapeutic targets, bridging molecular biology with clinical investigation.
×
